Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
52549-17-4
Molecular formula
C15H13NO3
Molecular weight
255.27 g/mol
Drug class
Propionic-acid non-steroidal anti-inflammatory drug (NSAID)ophthalmic cyclooxygenase inhibitor
Mechanism of action
Inhibits cyclooxygenase-mediated prostaglandin synthesis, reducing ocular inflammation, pain and inflammatory miosis. Topical ophthalmic administration produces local anti-inflammatory effects.
Indications / reported uses
Treatment of postoperative ocular inflammation and pain, and selected inflammatory eye conditions such as conjunctivitis or blepharitis, according to local product authorisation.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Pranoprofen PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pranoprofen Permitted Daily Exposure (PDE) report (the Pranoprofen PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pranoprofen Occupational Exposure Limit (OEL) report (the Pranoprofen OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.